ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,884Medicare Part D Prescriptions Filled, Including Refills

Rank: 18 out of 189

$396K Total Retail Price of All Prescriptions

Rank: 22 out of 189

254 Patients Receiving at Least One Drug in Part D
80%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Rhode Island
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 254 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

9% of this provider’s 254 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 6,480 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Rhode Island
METOPROLOL TARTRATE 308 262 1 6
AMLODIPINE BESYLATE 269 234 2 4
FUROSEMIDE 253 195 3 10
OMEPRAZOLE 235 171 4 3
SIMVASTATIN 230 179 5 2
METFORMIN HCL 209 178 6 7
WARFARIN SODIUM 203 197 7 14
LEVOTHYROXINE SODIUM 195 168 8 5
ATORVASTATIN CALCIUM 172 150 9 9
LISINOPRIL 171 141 10 1
TRAZODONE HCL 143 116 11 16
TRIAMTERENE-HCTZ 138 130 12 50
PRAVASTATIN SODIUM 131 117 13 13
HYDROCODONE-ACETAMINOPHEN 111 52 S3 14 11
HYDROCHLOROTHIAZIDE 109 86 15 8
GABAPENTIN 105 87 16 22
ATENOLOL 105 94 16 12
SERTRALINE HCL 100 99 18 17
PREDNISONE 90 75 19 38
CITALOPRAM HBR 87 68 20 15
CYMBALTA 87 56 20 59
SPIRIVA 73 62 22 33
METOPROLOL SUCCINATE 71 64 23 19
TRAMADOL HCL 68 51 24 32
CLOPIDOGREL 66 59 25 48
PANTOPRAZOLE SODIUM 66 65 25 58
GLIPIZIDE 66 59 25 39
LANTUS 64 46 28 56
TAMSULOSIN HCL 61 60 29 28
EXELON 61 61 29 101
DIOVAN 60 60 31 51
NAMENDA 58 58 32 49
MIRTAZAPINE 56 55 33 45
ESCITALOPRAM OXALATE 55 51 34 77
DONEPEZIL HCL 54 54 35 27
LEVOFLOXACIN 54 39 35 109
LOSARTAN POTASSIUM 54 44 35 20
CARVEDILOL 52 28 38 65
QUETIAPINE FUMARATE 51 47 39 78
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 30, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.